144 related articles for article (PubMed ID: 24308627)
21. Design, synthesis and biological evaluation of PEGylated Xenopus glucagon-like peptide-1 derivatives as long-acting hypoglycemic agents.
Han J; Wang Y; Meng Q; Li G; Huang F; Wu S; Fei Y; Zhou F; Fu J
Eur J Med Chem; 2017 May; 132():81-89. PubMed ID: 28342399
[TBL] [Abstract][Full Text] [Related]
22. Albumin-binding domain extends half-life of glucagon-like peptide-1.
Tan H; Su W; Zhang W; Zhang J; Sattler M; Zou P
Eur J Pharmacol; 2021 Jan; 890():173650. PubMed ID: 33049303
[TBL] [Abstract][Full Text] [Related]
23. Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity.
Cai X; Sun L; Dai Y; Avraham Y; Liu C; Han J; Liu Y; Feng D; Huang W; Qian H
Bioorg Med Chem; 2018 May; 26(9):2599-2609. PubMed ID: 29673717
[TBL] [Abstract][Full Text] [Related]
24. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
25. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
26. A novel thrombin-based triagonist with diabetes-protective and weight-lowering potential.
Zhang J; Zhang Z; Ma C; Zeng L; Zhang Y; Wang P; Xu L
Life Sci; 2020 Sep; 256():117853. PubMed ID: 32470452
[TBL] [Abstract][Full Text] [Related]
27. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
[TBL] [Abstract][Full Text] [Related]
28. A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice.
Li C; Yang M; Hou G; Liu S; Huan Y; Yu D; Sun S; Liu Q; Yan S; Shen Z
Biol Pharm Bull; 2017 Sep; 40(9):1399-1408. PubMed ID: 28626167
[TBL] [Abstract][Full Text] [Related]
29. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes.
Moffett RC; Patterson S; Irwin N; Flatt PR
Diabetes Metab Res Rev; 2015 Mar; 31(3):248-55. PubMed ID: 25256010
[TBL] [Abstract][Full Text] [Related]
30. Preparation and Pharmaceutical Characterizations of Lipidated Dimeric Xenopus Glucagon-Like Peptide-1 Conjugates.
Han J; Zhou F; Fei Y; Chen X; Fu J; Qian H
Bioconjug Chem; 2018 Feb; 29(2):390-402. PubMed ID: 29239601
[TBL] [Abstract][Full Text] [Related]
31. GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models.
Zhang M; Zhang Y; Peng X; He A; Wang Y; Deng Y; Cui C; Xue F; Wei B; Xing W; Qian Y; Mazuranic M; Chen W
Eur J Pharmacol; 2022 Aug; 928():175107. PubMed ID: 35718129
[TBL] [Abstract][Full Text] [Related]
32. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice.
Thorkildsen C; Neve S; Larsen BD; Meier E; Petersen JS
J Pharmacol Exp Ther; 2003 Nov; 307(2):490-6. PubMed ID: 12975499
[TBL] [Abstract][Full Text] [Related]
33. Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.
Zhong X; Yang S; Liu T; Ji S; Hu J; Li H
Eur J Med Chem; 2018 Apr; 150():841-850. PubMed ID: 29597167
[TBL] [Abstract][Full Text] [Related]
34. Formation of cyclic structure at amino-terminus of glucagon-like peptide-1 exhibited a prolonged half-life in vivo.
Cao Z; Li Y; Tang L; Xu W; Liu C; Zhang J; Gong M
Diabetes Res Clin Pract; 2012 Jun; 96(3):362-70. PubMed ID: 22284602
[TBL] [Abstract][Full Text] [Related]
35. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
36. A GLP-1/glucagon (GCG)/CCK
Zhao S; Yan Z; Du Y; Li Z; Tang C; Jing L; Sun L; Yang Q; Tang X; Yuan Y; Han J; Jiang N
Br J Pharmacol; 2022 Sep; 179(17):4360-4377. PubMed ID: 35484823
[TBL] [Abstract][Full Text] [Related]
37. The chronic administration of two novel long-acting
Han J; Meng T; Chen X; Han Y; Fu J; Zhou F; Fei Y; Li C
FASEB J; 2019 Jun; 33(6):7113-7125. PubMed ID: 30860869
[TBL] [Abstract][Full Text] [Related]
38. Stapled and
Chen X; Fu J; Zhou F; Yang Q; Wang J; Feng H; Jiang W; Jin L; Tang X; Jiang N; Yin J; Han J
J Med Chem; 2020 Nov; 63(21):12595-12613. PubMed ID: 33125843
[TBL] [Abstract][Full Text] [Related]
39. Xenopus-derived glucagon-like peptide-1 and polyethylene-glycosylated glucagon-like peptide-1 receptor agonists: long-acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities.
Han J; Fei Y; Zhou F; Chen X; Zhang Y; Liu L; Fu J
Br J Pharmacol; 2018 Feb; 175(3):544-557. PubMed ID: 29171021
[TBL] [Abstract][Full Text] [Related]
40. Rational design and evaluation of GLP-1 derivative for treating hyperglycemia combined with overexercise-induced myocardial injury.
Wang Y; Xia Z; Xie H; Dong J
Life Sci; 2021 May; 272():119030. PubMed ID: 33453242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
